Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro

European Journal of Clinical Pharmacology

Volumn 54, Issue 9-10, 1998, Pages 735-740

  Rasmussen, B Buur ^a   Nielsen, T L ^a   Brosen K ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

CYP2C19; Fluvoxamine; Proguanil

Indexed keywords

BROMOCRIPTINE; CYTOCHROME P450; DIHYDROERGOTAMINE; FLUVOXAMINE; KETOCONAZOLE; MIDAZOLAM; NORFLUOXETINE; PROGUANIL;

ARTICLE; CATALYSIS; DRUG DETERMINATION; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

ALGORITHMS; ANTIMALARIALS; ARYL HYDROCARBON HYDROXYLASES; CHLOROGUANIDE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FLUVOXAMINE; HUMANS; KINETICS; MITOCHONDRIA, LIVER; MIXED FUNCTION OXYGENASES; MODELS, BIOLOGICAL; SEROTONIN UPTAKE INHIBITORS;

EID: 0008789270     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050544     Document Type: Article

References (42)

1. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R (1995) Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 58: 399-403
2. Carrillo JA, Dahl ML, Svensson JO, et al (1996) Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 60: 183-190
3. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45: 1211-1214
4. Sperber AD (1991) Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 6: 460-462
5. Diot P, Jonville AP, Gerard F, et al (1991) Possible interaction between theophylline and fluvoxamine. Therapie 46: 170-171
6. Thomson AH, McGovern EM, Bennie P, Caldwell G, Smith M (1992) Interaction between fluvoxamine and theophylline. Pharm J 1 August: 137
7. Jeppesen U, Loft S, Poulsen HE, Brosen K (1996) A fluvoxamine-caffeine interaction study. Pharmacogenetics 6: 213-222
8. Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP (1992) Interaction between fluvoxamine and imipramine desipramine in four patients. Ther Drug Monit 14: 194-196
9. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R (1991) Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol 40: 119-120
10. Jerling M, Lindstrom L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16: 368-374
11. Hiemke C, Weigmann H, Härtter S, et al (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmaeol 14: 279-281
12. Spina E, Pollicino AM, Avenoso A, et al (1993) Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15: 243-246
13. Jeppesen U, Gram LF, Vistisen K, et al (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxeline, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51: 73-78
14. Skjelbo E, Brosen K (1992) Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34: 256-261
15. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34: 262-265
16. Rasmussen BB, Mäenpää J, Pelkonen O, et al (1995) Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39: 151-159
17. Vandel S, Bertschy G, Baumann P, et al (1995) Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 31: 347-353
18. Xu ZH, Xie HG, Zhou HH (1996) In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 42: 518-521
19. Jeppesen U, Rasmussen BB, Brosen K (1997) Fluvoxamine inhibits the CYP2C19-catalyzed biactivation of chloroguanide. Clin Pharmacol Ther 62: 279-286
20. Carrington HC, Crowther AF, Davey DG, Levi AA, Rose FL (1951) A metabolite of "Paludrine" with high antimalarial activity. Nature 168: 1080
21. Goldstein JA, Faletto MB, Romkes Sparks M, et al (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752
22. Helsby NA, Ward SA, Howells RE, Breekenridge AM (1990) In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br J Clin Pharmacol 30: 287-291
23. Ward SA, Helsby NA, Skjelbo E, et al (1991) The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism a panel study. Br J Clin Pharmacol 31: 689-692
24. Brosen K, Skjelbo E, Flachs H (1993) Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 36: 105-108
25. Skjelbo E, Mutabingwa TK, Bygbjerg IB, et al (1996) Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 59: 304-311
26. Birkett DJ, Rees D, Andersson T, et al (1994) In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3 A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 37: 413-420
27. Meier PJ, Mueller HK, Dick B, Meyer CA (1983) Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85: 682-692
28. Lowry OH, Rosebrough RJ, Farr AL, Randall RJ (1951) Protein measurement with folin phenol reagent. J Biol Chem 193: 265-275
29. Holford N (1990) MK model, Version 4. Biosoft, Cambridge
30. von Moltke LL, Greenblatt DJ, Harmatz JS, et al (1996) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276: 370-379
31. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI (1994) Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38: 23-31
32. Perucca E, Gatti G, Spina E (1994) Clinical pharmacogenetics of fluvoxamine. Clin Pharmacokinet 27: 175-190
33. Rasmussen BB, Nielsen TL, Brosen K (1998) Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol (in press)
34. Mäenpää J, Juvonen R, Raunio H, Rautio A, Pelkonen O (1994) Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochem Pharmacol 48: 1363-1369
35. Lemoine A, Gautier JC, Azoulay D, et al (1993) Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 43: 827-832
36. Bourrie M, Meunier V, Berger Y, Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277: 321-332
37. Nielsen TL, Rasmussen BB, Flinois J-P. Beaune P, Brosen K (1998) In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P450 3A4 in human liver microsomes. J Pharmacol Exp Ther (in press)
38. Funck-Brentano C, Becquemont L, Lenevu A, et al (1997) Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 280: 730-738
39. Helshy NA, Edwards G, Breckenridge AM, Ward SA (1993) The multiple-dose pharmacokinetics of proguanil. Br J Clin Pharmacol 35: 653-656
40. Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12: 415-416
41. Chiba K, Kobayashi K, Manabe K, et al (1993) Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 266: 52-59
42. Partovian C, Jacqz Aigrain E, Keundjian A, Jaillon P, Funck-Brentano C (1995) Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. Clin Pharmacol Ther 58: 257-263